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PURPOSE STATEMENT
Recent progress in the understanding of human autoimmunity provides a solid scienti®c
foundation on which to base rational therapies for autoimmune diseases. Pemphigus has
emerged as a classic example of an autoantibody mediated disease, and provides an excellent
model to study the mechanisms of such diseases and to develop new options to treat them.
This meeting brought together scientists working on basic aspects of human autoimmunity
with those working on pemphigus. Its goal was to review the current understanding of the
causes and treatments of pemphigus, and identify the most important areas for future research on
both pemphigus and other autoantibody mediated diseases.
The meeting focused on ®nding answers to the following questions:
dWhat is the etiology of autoimmune diseases in general, and pemphigus in particular?
dWhat are the factors affecting the autoimmune response characteristic of pemphigus?
dWhat are the most current treatments for pemphigus?
dWhat are the prospects for new treatments for pemphigus?
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Cleavage by Granzyme B is Strongly Predictive of Autoantigen Status: Implications for
Initiation and Progatation of Autoimmunity
L. Casciola-Rosen, F. Andrade, D. Ulanet, and A. Rosen
Johns Hopkins University School of Medicine, Bethesda, Maryland, U.S.A.
Systemic autoimmune diseases are a genetically complex, heterogeneous group of disorders in
which the immune system targets a diverse but highly speci®c group of intracellular autoantigens.
The molecules targeted are not uni®ed by common structure, function or distribution in control
cells but become clustered and concentrated in surface blebs when cells undergo apoptosis. We
have demonstrated that the majority of autoantigens targeted across the spectrum of human
systemic autoimmune diseases are ef®ciently cleaved by granzyme B in vitro and during cytotoxic
lymphocyte granule-induced death, generating unique fragments not observed during other forms
of apoptosis. These molecules are not cleaved by caspase-8, although this protease has a very similar
speci®city to granzyme B. The granzyme B cleavage sites in autoantigens contain amino acids in
the P2 and P3 positions that are preferred by granzyme B but are not tolerated by caspase-8. In
contrast to autoantigens, nonautoantigens are either not cleaved by granzyme B or are cleaved to
generate fragments identical to those formed in other types of apoptosis. This striking ability of
granzyme B to generate unique fragments is therefore an exclusive property of autoantigens and
uni®es the majority of molecules targeted in this spectrum of diseases. Several autoantigens targeted
in tissue-speci®c autoimmune diseases (e.g. tyrosinase) are also speci®cally cleaved by granzyme B.
These results focus attention on the role of the cytotoxic lymphocyte granule-induced death
pathway in the initiation and propagation of systemic autoimmunity.
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Genetic Predisposition to Autoimmune Diseases
J. Strominger
Harvard University,Department of Molecular & Cellular Biology, Cambridge, Massachusetts, U.S.A.
Most autoimmune diseases are linked to speci®c alleles of Class II histocompatibility complex
proteins. The association suggests that the linked allele is directly involved in the genesis of the
disease, although this has been proven in only a few cases. In the case of pemphigus vulgaris (PV),
the linkage is to a subtype of HLA-DR4, DRA/DRB1*0402. This subtype is distinguished from
other subtypes of DR4 by the presence of negatively charged residues in the P4 pocket, which
mandates a positively charged residue at P4 of the peptide. The immunodominant epitope of
desmoglein 3, amino acid residues 190±204, was predicted, veri®ed experimentally, and recently
substantiated by examination of additional patient material. The linkage to DRB1*0402 is found in
Ashkenazi Jews as well as in Iranian patients, but in non-Jewish patients of European descent and in
India and Pakistan, PV appears to be primarily linked to DQB1*0503. In addition to linkage to
Class II MHC genes, a large number of non-MHC genes distributed throughout the genome
contribute to susceptibility to autoimmune diseases, and some of these genes, none of which has
been de®nitively identi®ed, are involved in multiple autoimmune diseases. Much further work is
needed to clarify all the genetic factors that are involved in susceptibility to autoimmunity.
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What is Pemphigus?
R. Jordon
Department of Dermatology, University of Texas, Houston, Texas, U.S.A.
Historical perspective The term pemphigus was most likely in use in the ancient world, but the
®rst recorded instance was by hippocrates (460±370 BC) who described pemphigoid fever as
``pemphigodes pyertoi''. Galen (AD 131±201) named a pustular disease of the mouth as ``febris
pemphigodes''. In 1637, zacutus again uses the term ``febris pemphigodes'' to describe patients
with blisters of short duration. Desauvages (1760) described patients with high fever and blisters of
short duration as having ``pemphigus maior''. None of the above conditions is considered to be
true pemphigus, as their disease was of short duration and all patients recovered.
The ®rst recorded cases that probably represent true pemphigus were by McBride (1777) and
Wichmann (1791). Two of McBride's cases died of ``bloody ichor'' and ``putrid ulcers''.
Wichmann applied the term ``pemphigus'' to his patients and accurately describes ¯accid bullae and
painful oral ulcerations.
Pemphigus foliaceus was ®rst recognized by Cazenave in 1844, as a special, super®cial, rapidly
spreading form of pemphigus. Neumann, in 1886, describes a form of the disease with ``warty
granulations'' as pemphigus vegetans. Senear and Usher, in 1926, describe pemphigus
erythematosus, combining features of both pemphigus and lupus erythematosus. Auspitz (1881)
®rst described disruption of epidermal cells in patients with pemphigus, but not as a speci®c
®nding. Civatte, in 1943, clearly delineated this histopathologic hallmark and labeled it
acantholysis. He describes acantholysis (loss of cohesion) and intraepidermal bulla formation in
pemphigus vulgaris, pemphigus vegetans, and pemphigus foliaceus. These important pathologic
®ndings clearly separated pemphigus from other blistering skin diseases. In 1953, Lever de®ned the
disease entity bullous pemphigoid both clinically and histopathologically, clearly distinguishing it
from pemphigus. This ``pemphigus-like'' disease affected primarily elderly patients and was
characterized by subepidermal bulla formation.
The next breakthrough occurred in 1964 with the reporting of autoantibodies in the sera of
pemphigus patients, reactive with an ``intercellular substance'' of skin and mucosa, by Beutner and
Jordon using indirect immuno¯uorescence. They later showed these same autoantibodies ®xed in
pathologic sections using direct immuno¯uorescence methods. In 1967, they also demonstrated
autoantibodies in sera and skin specimens from patients with bullous pemphigoid but reactive with
the basement membrane zone. These latter ®ndings clearly separate bullous pemphigoid from
pemphigus, and establish it as a distinct bullous skin disease.
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Fogo Selvagem: An Environmentally Triggered Form of Pemphigus Foliaceus
L. Diaz
Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,
U.S.A.
Although Fogo Selvagem (FS) was originally described, and is still most frequently found in Brazil
there are reports of other foci of endemic pemphigus foliaceus (PF) in Colombia and Tunisia. The
clinical, histological and immunological features of FS are similar to those of the nonendemic form
of PF seen in the U.S.A. and around the world. As in the nonendemic form of PF, FS is
characterized by super®cial subcorneal blisters and pathogenic autoantibodies that are speci®c for
the ectodomain of dsg1. FS, however, shows several unique and remarkable features such as the
geographic and temporal clustering of cases, the increased frequency of cases among young adults
and children, the increased frequency of familial cases, and an association with certain distinct
HLA-DR alleles.
We have recently described two settlements of Amerindian natives in Brazil that exhibit a high
prevalence of FS, a Xavante Reservation located in the eastern region of the state of Mato Grosso
and the Terena Reservation of Limao Verde. The Limao Verde reservation has a population of
1200 individuals with a prevalence of FS of 3.2% and an incidence of 1±4 new cases per year. We
evaluated the presence of dsg1-speci®c autoantibodies in the sera of FS patients from the Limao
Verde reservation and from a large group of normal donors from the U.S.A., Japan and Brazil using
a highly sensitive and speci®c desmoglein1 (dsg1)-ELISA assay. The control sera from Brazil
included samples from cities located at different distances from the Limao Verde reservation. Anti-
dsg1 autoantibodies were absent in the control sera from the U.S.A. and Japan, which included
samples from normal individuals and patients with other cutaneous autoimmune blistering diseases
such as bullous pemphigoid, herpes gestationis and lupus erythematosus. Intriguingly, antidsg1
autoantibodies were detected not only in the sera of FS patients but also in the sera of several
normal controls from the reservation and from Brazilian cities. The percentage of ELISA-positive
sera among the normal control population was inversely related to the distance from the endemic
focus of Limao Verde. In ®ve FS cases followed in Limao Verde for several years, antidsg1
autoantibodies were present in blood samples obtained 1±5 years prior to the onset of the disease.
However, the titers of antidsg1 antibodies increased several fold once the disease was clinically
apparent. These results suggest that in an area endemic for FS, such as the Limao Verde reservation,
certain members of the population become sensitized to an environmental antigen(s) producing
antidsg1 autoantibodies that, in the course of several years, can lead to FS. The molecular
mechanisms of antidsg1 formation and the putative environmental antigen(s) in FS remain to be
determined. It is feasible that epidermal dsg1 and the environmental antigen(s) may share certain
cross-reactive epitopes that are relevant to the immunopathogenesis of this disease.
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Paraneoplastic Pemphigus ± Autoimmunity and Cancer
G. Anhalt
Dermatoimmunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
Paraneoplastic pemphigus (PNP) is a recently described form of pemphigus that is de®ned by the
following: (a) the presence of mucosal ulcerations and blisters and a polymorphous skin eruption in
the context of an occult or known neoplasm (b) histologic ®ndings of vacuolar interface change,
keratinocyte necrosis, and intraepidermal cell-cell detachment (suprabasilar acantholysis) (c)
deposition of IgG and C3 on epidermal cell surfaces and variably also along the basement
membrane zone (d) serum autoantibodies that bind to the cell surface of strati®ed squamous
epithelia and also to simple, columnar, and transitional epithelia (e) serum autoantibodies that
recognize a characteristic antigen complex of 250, 230, 210, 190, and 170 kDa peptides. These are
now known to represent desmoplakins I and II (250, 210 kDa, the bullous pemphigoid antigen
1(230 kDa), envoplakin (210 kDa) and periplakin (190 kDa). Recent studies demonstrated that
these patients also produce antibodies against desmoglein 3 (Dsg3) and Dsg1, and that anti-Dsg3
IgG plays a primary pathogenic role in inducing loss of cell adhesion of keratinocytes to cause
blister formation in paraneoplastic pemphigus. The 170 kDa antigen is a transmembrane cell surface
protein, which is yet to be identi®ed. Serologic de®nition of the disease is dependent upon
demonstration of antibodies against the plakin proteins, by immuno¯uorescent or immunochem-
ical techniques. Refractory stomatitis is the most characteristic clinical feature of the disease, and in
the past, many cases of erythema multiforme, Stevens Johnson syndrome or toxic epidermal
necrolysis associated with hematologic neoplasms were probably unrecognized PNP.
Associated neoplasms are non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL),
Castleman's disease, thymomas, and poorly differentiated spindle cell sarcomas. In patients less than
20 years of age, essentially all cases are associated with Castleman's disease. Non ± Hodgkin's
Lymphomas and chronic lymphocytic leukemias are ``frequently'' complicated by autoimmune
phenomena, such as autoimmune cytopenias, and we suspect that PNP is another example of
induction of autoimmunity by these speci®c neoplasms. PNP also occurs in domestic animals
(horses and dogs), with similar associated tumors and similar outcomes.
In patients with a benign neoplasm that can be completely resected by surgery, recovery is
anticipated, but over a period of 12±24 months. The mortality of PNP associated with malignant
neoplasms still approaches 95% by two years post diagnosis. Treatment of the underlying neoplasm
by chemotherapy does not improve the autoimmune disease, once it is initiated by the tumour.
Some cases of CLL are responsive to combined treatment with prednisone, cyclosporine and
cyclophosphamide, but cases of NHL do not respond reliably to any therapy. Many fatalities are
now recognized to be secondary to pulmonary involvement. There is evidence that PNP affects
the epithelium of large and small airways, with sloughing of the respiratory epithelium, resulting in
fatal bronchiolitis obliterans.
Future challenges include better de®nition of the mechanisms by which these tumors induce
autoimmunity, and more effective therapies for those patients with associated lymphomas.
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Pemphigus and bullous pemphigoid
G. Anhalt
Dermatoimmunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
Pemphigus and bullous pemphigoid are distinct autoimmune blistering skin diseases that are
characterized by the presence of autoantibodies directed against speci®c adhesion molecules. This
talk will compare and contrast the molecular mechanisms of blister formation of these two diseases,
and demonstrate how knowledge of these pathophysiologic mechanisms can provide a rational
therapeutic approach.
In pemphigus vulgaris, histologic examination shows intraepithelial blistering, and in¯ammatory
cellular in®ltration can be minimal or absent. Direct immuno¯uorescence shows IgG and variable
C3 deposition on cell surfaces. Passive transfer of human IgG autoantibodies into neonatal mice
precisely reproduces the disease, and seems to do so by down-regulating the adhesive function of
the antigen. The binding of pemphigus antibodies does induce other events, such as activation of
complement and plasminogen activator, but these do not seem to in¯uence acantholysis
signi®cantly. Pemphigus antibodies can readily induce blistering in mice depleted of functional
complement, or pretreated with high doses of corticosteroids, which effectively abolished
plasminogen activator activity. The importance of desmoglein 3 in cellular adhesion was further
demonstrated by genetically engineered mice with disruption of the desmoglein 3 gene. These
mice demonstrated runting, due to intraoral lesions typical of pemphigus. These data establish that
the goal of therapy in pemphigus must be directed towards reducing synthesis of autoantibodies, by
systemic corticosteroids, alone or in conjunction with immunosuppressive drugs. Topical therapies
have no role in management. Complications secondary to the use of very high dose corticosteroids
contribute to the current mortality rate.
We employ the following treatment steps: (1) Prednisone at doses no greater than 1 mg/kg/day
(2) prednisone plus a nonalkylating agent such as azathioprine or mycophenolate mofetil (3)
prednisone plus an alkylating agent ± cyclophosphamide or chlorambucil, and (4) prednisone plus
an alkylating agent plus short-term plasmapheresis.Histologic examination in bullous pemphigoid
shows subepidermal blistering, with large numbers of in®ltrating polymorphonuclear cells. Direct
immuno¯uorescence shows linear IgG and C3 deposition along the basement membrane. Indirect
immuno¯uorescence shows circulating IgG BMZ autoantibodies.
Patients Sera recognize two hemidesmosomal protein antigens ± the bullous pemphigoid
antigen 1 (bpag1 or bp230 ag), and the 180 kda, bullous pemphigoid antigen 2 (bpag2 or bp180
ag). Unlike pemphigus antibody ± induced cell detachment, in which antibody binding to the cell
adhesion molecule directly induced cellular detachment, bullous pemphigoid antibodies induce a
cascade of in¯ammatory events that are requisite for blister formation. Blistering occurs only after
the sequence of antibody binding to the bp 180 ag, complement activation and polymorphonuclear
cell in®ltration. These data explain clinical observations about the disease and show why anti-
in¯ammatory drugs have a role in treatment of bullous pemphigoid.
Prednisone is most useful, and is often rapidly effective at a dose of 0.5 mg/kg/day. In mild cases,
anti-in¯ammatory drugs such as dapsone or tetracycline and niacinamide may have steroid-sparing
effects. In cases of moderate severity, azathioprine 2±3 mg/kg or mycophenolate mofetil at a dose
of 30 mg/kg/day can be very effective. More aggressive treatment with plasmapheresis and
cyclophosphamide is rarely required, but when needed is highly effective.
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Pemphigus: Drugs and Infectious Agents as Inducing Factors
V. Ruocco
Department of Dermatology, 2nd University of Naples,Naples, Italy
The onset and course of pemphigus depend on a variable interaction between predisposing and
inducing factors. Genetic predisposition is known to be associated with human leukocyte antigens
(HLA), in particular with DR4, 14; DQ 1,3 [1]. The genetic background alone, though essential, is
not by itself suf®cient to initiate the autoimmune response, as proven by the reports of pemphigus
in only one of two monozygotic twins [2] and in only two of three siblings with identical
predisposing haplotype [3]. The intervention of inducing or triggering factors seems to be crucial
to set off the full-blown disease.
Even if in the majority of patients no inducing agent can be detected (idiopathic pemphigus), in several
cases a meticulous clinical history discloses facilitating factors (induced or triggered pemphigus).
Induced pemphigus proper refers to a condition where exogenous factors play a major role, so that the
disease regresses after the inducing factor is eliminated, even without treatment. In triggered pemphigus,
endogenous factors are more important and the inducing factors seem to only trigger, in a casual and
non speci®c manner, a disimmune mechanism previously programmed and ready to be set off, so that,
in spite of elimination of the inducing factor, the disease self-perpetuates [4].
Inducing factors are numerous and heterogeneous, but in most cases the induction is related to
certain drugs (thiols, ACE-inhibitors, phenols, NSAIDs, interferons, and other cytokines) or some
viruses (herpesviruses). The involvement of an inducing agent in the pathomechanisms leading to the
outbreak of pemphigus is often suspected on the basis of circumstantial evidence, but sometimes it can
be demonstrated with certainty [4±7].
As for certaindrugs, their potential of provokingacantholytic changes has beencon®rmedby several
experimental investigations [6]. In particular, a drug may provoke acantholysis by interfering with the
keratinocyte membrane biochemistry (biochemical acantholysis) and/or with the immune balance, both
cellular and humoral (immunological acantholysis) [5].
As for herpesviruses, frequently involved inpemphigus induction, but also for otheroccasional virus
infections (e.g. cold, ¯u), the possibility exists that interferons and other cytokines, which the host
produces as a consequenceof thevirus attack, overactivate the immune system leading to the antibody-
mediated acantholytic autoimmune disease [8].
For practical purposes, avoiding or limiting the interaction of precipitating factors with the
pemphigus-prone genetic background may be a useful precaution in the management of pemphigus
patients, because it can improve the ef®cacy of conventional treatments, reduce risks of relapses and, in
some cases (induced pemphigus proper), even result in a cure.
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The Pathogenic Autoantibody Response of Animal Models in Pemphigus
M. Amagai
Department of Dermatology, Keio University, School of Medicine, Tokyo, Japan
Pemphigus is a unique and interesting autoimmune disease, in which IgG autoantibodies play a
pathogenic role and cause blister formation. The autoantibodies are directed against desmoglein
(Dsg), an epidermal cell-cell adhesion molecule. Recently we have generated an active disease
mouse model of pemphigus vulgaris (PV) with a unique approach using autoantigen knockout
mice, in which self tolerance of the defective gene product is not acquired. We immunized
Dsg3±/± mice with recombinant Dsg3 (rDsg3), the target antigen of PV. Then, splenocytes from
these mice were adoptively transferred to Rag2±/± immunode®cient mice that express Dsg3.
Similar to PV patients, the recipient mice stably produced pathogenic anti-Dsg3 IgG for over
6 months and caused blisters due to loss of cell-cell adhesion with the characteristic histology. This
model was further characterized to investigate the cellular mechanism of tolerance loss against
Dsg3. Puri®ed T and B cells from Dsg3±/±, Dsg3+/±, and Dsg3+/+ mice were mixed with
various combinations and transferred to Rag2±/± mice. The PV phenotype was observed only
with a combination of Dsg3±/± T and Dsg3±/± B cells but not with the other combinations,
suggesting that loss of tolerance against Dsg3 in both B and T cells is required for the development
of the autoimmune state of PV. Furthermore, we have generated pathogenic anti-Dsg3
monoclonal antibodies from PV model mice. Our model is a valuable tool to dissect cellular
and molecular mechanism of autoantibody production as well as to develop novel therapeutic
strategies.
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Do T Lymphocytes Play a Role in the Development of Pemphigus?
M.-S. Lin
Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,
U.S.A.
Pemphigus is a cutaneous autoimmune disease characterized by intraepidermal blisters and
circulating autoantibodies against desmosomal components, desmoglein-1 (Dsg1) and/or
desmoglein-3 (Dsg3). Using a passive transfer animal model, we have demonstrated that puri®ed
autoantibodies against Dsg1 and Dsg3 can induce diseases similar to pemphigus foliaceus (PF) or
pemphigus vulgaris (PV), respectively. These results indicate that anti-Dsg antibodies are directly
involved in the tissue damage, which occurs in pemphigus. Since the production of antibodies in
the T-dependent immune responses usually requires the assistance of antigen-speci®c T
lymphocytes, it is proposed that T cells may play an essential role in the autoimmune reaction
in patients with pemphigus by recognizing Dsg and regulating the secretion of harmful anti-Dsg
antibodies. Using endemic PF, fogo selvagem (FS), as an example, we showed that T cells from
these patients responded to Dsg1 in a dose dependent manner. This T cell reaction was speci®c to
patients with FS because T cells from other patient groups, as well as normal individuals, failed to
proliferate to Dsg1. Further, T cell lines and clones derived from FS patients were shown to
speci®cally respond to Dsg1, but not to Dsg3 or BP180 antigens, suggesting that these T cells may
be responsible for the autoimmune responses against Dsg1 in the disease. Characterization of these
T cell lines and clones revealed that they are CD4+ memory T cells secreting a Th2-like cytokine
pro®le, a subset of T cells supporting the production of antibodies. In summary, our data provide
evidence that Dsg-speci®c T cells from patients with pemphigus may play a role in the
development of the disease at a stage leading to the production of autoantibodies. Moreover, we
demonstrated that the majority of FS T cell clones reacted with a 15 amino acid Dsg1 peptide that
was predicted to be presented by FS associated MHC II molecules, HLA-DRB1*0102, 0401,
1402, and 1406. This information will allow us to identify the peptide that may trigger the FS
autoimmune reaction and help to design a peptide antagonist that can inhibit the Dsg1-speci®c T
cells in the near future.
010
Other Antigens Recognized by Pemphigus Autoantibodies
T. Hashimoto
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
The major autoantigens for classic types of pemphigus are desmogleins 1/3 (Dsg1/Dsg3).
However, the other proteins are also recognized by some types of pemphigus. For example,
paraneoplastic pemphigus (PNP) sera react with various plakin family proteins, including plectin,
desmoplakins I/II, BP230, envoplakin and periplakin, as well as an unknown 170 kDa protein, by
either immunoprecipitation and immunoblotting. By a novel cDNA transfection methods using
cDNAs of human desmocollins (Dsc) 1±3, we previously showed that IgA antibodies of subcorneal
pustular dermatosis type IgA pemphigus react speci®cally with Dsc1 on the cell surfaces of COS-7
cells, which were transfected with eukaryotic expression vector containing human Dsc1 cDNA.
However, the presence of IgG anti-Dsc autoantibodies is still controversial, and antibodies to Dsc2
and Dsc3 have not been clearly identi®ed. Therefore, in the present study, we further analyzed
autoantibodies against envoplakin, periplakin and Dsc1±3 in more details by various methods.
In the ®rst study, using bacterial expression vectors containing polymerase chain reaction-
ampli®ed cDNAs, we prepared variously truncated recombinant glutathione-S-transferase-fusion
proteins of envoplakin and periplakin, which presented N-terminal, central and C-terminal
domains of each protein, as well as so-called C-terminal homologous domain of envoplakin. By
immunoblotting using these 7 recombinant proteins, we demonstrated that most of the 26 PNP
sera reacted very strongly with multiple recombinant proteins of envoplakin and periplakin, except
for C-terminal homologous domain of eriplakin. We also examined the reactivity of other
blistering diseases including pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid
with the 7 proteins, and found that a few of these non-PNP sera showed a weak reactivity with
some of the recombinant proteins. Interestingly, some sera showed relatively strong reactivity with
C-terminal homologous domain of periplakin, to which paraneoplastic pemphigus sera reacted less
frequently. These results indicate that the immunoblotting using the recombinant proteins of
envoplakin and periplakin should be a useful tool for the diagnosis of PNP. In addition, although
non-PNP sera occasionally show a weak reactivity with envoplakin and periplakin, the
pathogenecity and the mechanism of antibody production in these cases may be different from
those in PNP.
Next, we have produced recombinant proteins containing entire extracellular domains of
human Dsc1±3 by baculovirus-expression system, and subsequently established an enzyme-linked
immunosorbent assays (ELISA) for both IgG and IgA antibodies using these recombinant Dscs. By
this ELISA, none of the 45 sera of classic types of pemphigus showed IgG antibodies to any Dsc. In
contrast, one atypical pemphigus serum showed both IgG and IgA antibodies to Dsc1, which were
completely absorbed by incubation with Dsc1 baculoprotein. Furthermore, this ELISA detected
IgA anti-Dsc3 antibodies and IgA antibodies to both Dsc2 and Dsc3 in one each of atypical
pemphigus case. This reactivity was con®rmed by the positive IgA immuno¯uorescence staining
with human Dsc2 and Dsc3 expressed on COS-7 cells transfected with cDNA of each Dsc. These
results suggest that, both IgG and IgA autoantibodies against all of Dsc1±3 are present in the sera of
nonclassical types of pemphigus.
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The Importance of Non-Desmoglein Targets of Pemphigus Autoimmunity
S. Grando
University of California, Davis, California, U.S.A.
Most of organ-speci®c autoimmune diseases are associated with autoimmunity against cell-surface
receptors. Acantholytic activity of pemphigus IgGs harbors pharmacologic effects on keratinocyte
shape and adhesion. Approximately 85% of patients with pemphigus vulgaris (PV) and pemphigus
foliaceus develop antibodies to acetylcholine receptors (AChRs) expressed on the cell membrane of
epidermal keratinocytes. Classic studies showed that human keratinocytes express several muscarinic
AChR subtypes as well as several types of heteromeric and homomeric nicotinic AchR channels.
These cholinergic receptors regulate transmembrane Ca2+ ¯ux and intracellular metabolism and have
been implicated in mediating physiologic control of keratinocyte adhesion and motility. The
immunopharmacologic action of pemphigus IgGs may therefore be mediated by alterations of
physiologic control of keratinocyte shape and adhesion through a G protein coupled-metabotropic
receptor and/or an ion channel. To identify the molecular structure of keratinocyte AChR(s) targeted
by pemphigus antibodies, we performed blocking indirect immuno¯uorescence experiments.
Preincubation of monkey esophagus with PV antibodies blocked speci®c staining of the keratinocyte
cellmembranewith rabbit antibody to a9AChR, indicating that this ®rst of its kindmixed muscarinic-
and-nicotinic AChR is targeted by PV autoimmunity. In contrast to distinct in vitro acantholytic
activity of antia9 antibody, its intraperitoneal administration to neonatal mice did not induce PV-like
mucocutaneous changes. This prompted our search for other novel targets of PV autoimmunity. The
PV IgG eluted from a 75-kDa keratinocyte protein band both stained epidermis in a PV-like pattern
and induced acantholysis in keratinocyte monolayers. Screening of a keratinocyte cDNA library with
this antibody identi®ed clones carrying cDNA inserts encoding a novel molecule exhibiting ~40%
similarity with annexin-2, named pemphaxin (PX). PX speci®cally binds acetylcholine, suggesting
that it can be one of the keratinocyte cholinergic receptors targeted by PV antibodies. Preabsorption of
PV sera with recombinant PX eliminated acantholytic activity. However, this antibody alone did not
cause skin blisters in vivo. The lack of symptoms in neonatal mice injected with antia9 or anti-PX
antibodies is not surprising, because the integrity of the epidermal barrier in higher species relies on
more than a single molecule.
Therefore, we conclude that pemphigus is a complex process involving several antigen systems. To
trigger pemphigus, anti-AchR antibody may be needed to functionally complement the effect of
antidesmoglein antibodies. To test a hypothesis that cholinomimetics ± the drugs that speci®cally bind
to and activate AChRs ± may counteract acantholytic effects of PV IgG, we treated neonatal micewith
induced pemphigus using the cholinomimetic carbachol and obtained signi®cant decrease of the
extend of cutaneous acantholysis (p < 0.05). Currently, we are conducting a clinical trial of
cholinomimetics in the treatment of patients with PV ort PF. The goal is to replace glucocorticoids
with a well-tolerated acetylcholinesterase inhibitor, Mestinon (pyridostigmine bromide), given alone
or in combination with topical application of a cream containing the cholinomimetic drug pilocarpine
hydrochloride, Pilopine HS' Gel. Thus, our studies have re-de®ned the epitopes and mechanisms
leading to blistering in pemphigus, and are expected to lead to the development of nonsteroidal
therapy for pemphigus.
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Pemphigus Vulgaris: The Pathogenic Activity of PV-FAB is Plakoglobin-Dependent
E. MuÈller, R. Caldelari, A. de Bruin, D. Baumann, T. Hunziker, and M. Suter
Institute of Animal Pathology1 and Department of Clinical Research2, University of Berne, Berne,
Switzerland
With the aim to investigate the molecular mechanisms leading to blister formation in pemphigus
vulgaris (PV), we recently developed an in vitro model based on long-term keratinocyte cultures of
wild-type and plakoglobin knock-out (PG±/±) mice, and uncovered a pivotal role for this plaque
protein in lesion formation. Here we focused on the involvement of plakoglobin in the PV IgG-
induced break-down of desmosome-mediated adhesion at the plasma membrane. Using
immuno¯uorescence studies we found that binding of PV IgG to wild-type or PG±/± cells
induced clustering of all investigated desmosomal proteins. We subsequently addressed whether
this PV IgG-induced event is a by-stander phenomenon due to the bivalence of the antibody or is
part of the pathdgenetic process. Using monovalent PV-Fab fragments on wild-type keratinocytes,
clustering and break-down of the desmosomal organization concurrent with keratin retraction was
similar than with bivalent PV IgG. In contrast, despite binding of PV-Fab to PG±/± cells, clustering
was abrogated and keratin retraction did not occur in these cells. In summary, our dual in vitro
model allowed to separate two as yet undescribed activities of the antibody. Namely, a strong
cross-linking activity is exerted by bivalent PV IgG which is not required for lesion formation and
is independent of plakoglobin. The second activity relays on plakoglobin, is independent of
antibody valence and is pathogenic as it causes disruption of the entire desmosomal organization.
Collectively our ®ndings corroborate dependence of lesion formation on a plakoglobin-mediated
cellular response, and thus attribute an important role to this plaque protein in maintaining the
epithelial architecture. A better knowledge of these mechanisms will hopefully form the bases to
develop alternative therapeutic strategies in pro®t of the PV patient.
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The Role of Antigen Distribution in the Localization of Pemphigus Lesions
M. Mahoney
Department of Dermatology and Cutaneous Biology,Thomas Jefferson University, Philadelphia,
Pennsylvania, U.S.A.
Pemphigus is a group of autoimmune blistering disorders of the skin and mucous membranes resulting from
loss of epithelial cell-cell adhesion due to circulating pathogenic autoantibodies. These antibodies are
directed against several epithelial proteins, including the cadherins, desmoglein 1 (Dsg1) and desmoglein 3
(Dsg3). Desmogleins are transmembrane glycoproteins that function as adhesive components of
desmosomes, the intercellular junctions that are critical for maintaining cell-cell adhesion, tissue integrity,
and organ function. The two classic forms of pemphigus are pemphigus foliaceus (PF) and pemphigus
vulgaris (PV). PF blisters occur in the super®cial epidermis and spare the mucous membranes, although PF
anti-Dsg1 antibodies have been shown to bind to the entire epidermis and to the super®cial epithelia of oral
mucosa. In contrast, PV patients develop antibodies against both Dsg1 and Dsg3. The hallmark pathogenic
feature is acantholysis of epidermal cells as well as epithelial cells of the oral mucosa, and the blisters
occurring within the basal and suprabasal layers. To correlate pemphigus antibody pro®les with tissue
distribution of desmogleins and explain blister localization in PF and PV, we used the neonatal mouse
model of pemphigus by passive transfer of pemphigus IgG to normal and DSG3 knockout mice (DSG3±/±
). First we demonstrated by immunostaining on mouse tissues that the distributions of Dsg1 and Dsg3 are
similar to that in human tissues. Dsg1 is expressed throughout the epidermis and the oral mucosa. In
contrast, Dsg3 is found only in the basal layer of the epidermis, while it is expressed throughout the entire
oral mucosa. To demonstrate the role of Dsg3 in limiting blister formation in PF, we injected mice with
1 mg of PF IgG. This low dosage (1/10 of the usual amount) of PF IgG caused small isolated blisters in
DSG3+/± or +/+ mice but caused extensive blistering in DSG3±/± mice. Thus, animals devoid of Dsg3
are more susceptible to blister formation by anti-Dsg1 antibodies. We hypothesized that blisters occur in PF
where Dsg1 is found without concomitant Dsg3, namely, in the super®cial epidermis. As predicted, PF IgG
only caused super®cial epidermal acantholysis and no mucous membrane lesions in DSG3+/± or +/+ mice
(n = 26), but in DSG3±/± mice resulted in super®cial and deep epidermal acantholysis and marked
acantholysis of tongue mucosa (n = 7). These data also clarify the recent observation that PV patients with
exclusively oral lesions have only anti-Dsg3 antibodies, while patients with skin involvement have also
anti-Dsg1 antibodies, indicating that both antibodies may be necessary to interfere with both desmogleins
in the deep epidermis. We con®rmed the pathogenicity of the anti-Dsg1 antibodies from PV sera in deep
epidermis by showing extensive blistering with deep epidermal acantholysis in PV IgG injected DSG3±/±
mice (n = 3). Furthermore, while PV sera containing anti-Dsg3 antibodies alone were inef®cient at causing
blister formation in mice (n = 8), anti-Dsg1 antibodies increased the pathogenicity of PV sera. These data
suggest that pemphigus autoantibodies inhibit the adhesive function of desmoglein proteins and that either
Dsg1 or Dsg3 alone is suf®cient to maintain keratinocyte cell-cell adhesion.
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``Combined Immunosuppressive Therapy in Pemphigus.'' Looking for Effectiveness
and Safety
H. Nousari
Dermatoimmunology, Johns Hopkins University, Baltimore, Maryland, U.S.A.
Pemphigus is an autoimmune blistering disease that affects skin and/or mucose membranes. The prognosis
of this disease has dramatically improved with the use of immunosuppressive therapy. However the actual
morbidity and mortality is due to the side-effects of these immunosuppressive drugs mainly by the misuse
of systemic corticosteroids. The goal in immunosuppressive therapy is to have the most effective and safest
regimen for patients. At present time this goal can be only achieved by combination therapy of drugs.
The standard initial therapy in pemphigus patients is still systemic corticosteroids. However, the
overdose and/or prolonged exposure of corticosteroids are the main culprit of the complications seen in
patients receiving immunosuppresive therapy. Therefore, In this study we tried to ®nd the drugs that at
appropriate doses upon combination with corticosteroids can achieved the goal of immunosuppressive
therapy:
Ef®cacy and safety Upon combination of drugs three therapeutics effects can be encountered. (1)
additive (2) synergistic and (3) antagonistic. We used immunosuppressive agents that have effective
inhibition on B Lymphocytes (immunologic cells producing the pathogenic antibodies in pemphigus) as
well as on T lymphocytes (regulatory cells of the immune system) (1) An additive effect is the one in which
the concept of ``Corticosteroid Adjuvant Therapy'' was originated. In this effect, the addition of the
adjuvant drugs will allow the tapering down of the corticosteroid. This combination is not associated with a
better therapeutic effect than that given by prednisone alone, but it will minimize the exposure to
prednisone and thus the corticosteroid-side-effects. The combination of prednisone 1 mg/kg/day (ideal
and not actual weight) with azathioprine (Imuran) 3±4 mg/kg day or prednisone 1 mg/kg/day with
mycophenolate mofetil (Cellcept) 30±45 mg/kg/day has shown to be ``additive'' in pemphigus patients. (2)
Synergistic effect is the one that ideally should be obtained in patients in whom corticosteroid therapy failed
to control the disease. Thus the second drug is more effective (usually more toxic too) than corticosteroids.
The combination of of prednisone 1 mg/kg/day and cyclophosphamide (Cytoxan) 2±3 mg/kg/day has a
synergistic effect, and even higher effect was the addition of plasmapheresis. These combinations are the
most effective but also more toxic than the additive regimens, thus they are reserved for severe cases or
patients that failed additive therapy. (3) Antagonistic effect is the one that every single doctor is trying to
avoid. Since the drugs share the mechanisms of action, upon combination the ultimate therapeutic effect
gets diminished and the toxicity gets exponentially increased. The following combinations are antagonistic
(a) two corticosteroids: prednisone with dexamethasone (b) two antimetabolites azathioprine with
mycophenolate mofetil or (c) two alkylating agents cyclophosphamide with chlorambucil. Combined
immunosuppressive therapy using drugs that have an effective inhibitory action on the synthesis of
pathogenic antibodies is effective and safe in pemphigus patients.
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Use of Plasmapheresis and Immunosuppression in the Treatment of Pemphigus Vulgaris
M. Unger and D. Sauder
Department of Dermatology, Johns Hopkins University, Baltimore, Maryland, U.S.A.
Plasmapheresis can be used in immune and in¯ammatory conditions to remove antibody, antigen,
antibody-antigen complexes, or a combination of the above. Plasmapheresis was ®rst utilized in the
treatment of auto-antibody mediated diseases in 1975, when it was applied to a patient with Goodpastures
syndrome (1). Three years later, it was adopted as a therapeutic approach in the treatment of pemphigus
vulgaris (2). In pemphigus, the rationale for plasmapheresis is to remove pathogenic antibodies to
desmoglein I or III.
The only controlled study of the use of plasma exchange in pemphigus was published in 1988 (3). This
was a 40 patient randomized control trial, comparing patients receiving prednisolone alone vs. prednisolone
plus plasma exchange. The study found no signi®cant bene®t, however, no immunosuppressive agent was
used as an adjuvant. The absence of an administered immunosuppressive agent was a major ¯aw in this
study, since pathogenic B-cells begin to synthesize new auto-antibodies soon after plasmapheresis. In fact,
as quickly as three hours after plasmapheresis, auto-antibody levels may reach levels equivalent or exceeding
those that existed prior to plasmapheresis. This phenomenon, referred to as the rebound phenomenon, is
achieved through a negative feedback mechanism involving pathogenic B-cells activated by the sudden
drop in circulating levels of auto-antibodies. Thus, the use of immunosuppressive agents is necessary to
reduce this pathogenic B-cell response.
While there are no controlled studies on the use of plasmapheresis and immunosuppressive agents, there
are numerous anecdotal reports (4±20). Most recently, Marcusson published a case of pemphigus foliaceous
successfully controlled with plasma exchange during a 10-year period(5). The patient, when treated with
plasma exchange, prednisone, and azathioprine, went into complete remission, thereby allowing
discontinuation of systemic therapy. The patient is now maintained with plasma exchange on an 8±
10 week basis. In a further series, Roujeau et al (13) published an uncontrolled trial on 10 patients showing
that 8 of 10 had clinical improvement and that all patients had a decreased antibody level. In the December
2000 issue of the Journal of American Academy of Dermatology (21), 7 pemphigus patients treated with
plasmapheresis were reviewed. Each treatment consisted of one volume exchanged (approximately 15
milliliters per kilogram). The replacement solution was a 5% albumin solution. As was the case in previous
studies, in most patients plasmapheresis produced dramatic and immediate reductions in serum antibody
titres. Furthermore, this was generally associated with signi®cant clinical improvement. Our current
recommendations are to follow plasmapheresis with IV cyclophosphamide (0.5% gm/m2) to prevent the
rebound phenomenon.
Plasma exchange is not without risk. Complications include nausea, vomiting, electrolyte disturbances,
depletion of coagulation factors, hypotension or hypertension, and arrhythmia. The most severe reactions,
hypotension and cardiac arrhythmia, emerge in roughly 25% of cases. Other serious reactions include CNS
disturbances, dyspnea, abdominal pain and vomiting and chest pain. There are also limitations in the use of
plasma exchange: ®rstly, it is not ef®cient in removing large amounts of antibody; secondly, it is clearly not
speci®c for pathogenic antibodies, as all immunoglobulins are reduced; ®nally, in most cases plasmapheresis
requires the use of replacement ¯uids. There is a signi®cant higher risk when plasma is used as a
replacement ¯uid as opposed to some other form of replacement ¯uid and colloid. When blood products
are used as a component of replacement ¯uids an additional expense is introduced, as well as a possibility of
transmissible disease. Furthermore, limited availability is problematic with some blood products.
A number of considerations should be made when considering the use of plasmapheresis in the treatment
of pemphigus vulgaris. Plasmapheresis is not recommended for all patients, rather it should be restricted to
the following situations ± life threatening pemphigus, resistant disease, and persistent disease. It should also
be considered in patients with unacceptable side-effects from therapy such as aseptic necrosis of joints
induced by corticosteroid use. Patients with severe mucosal disease, leading to an inability to take oral
medication, may bene®t from plasmapheresis. Generally, plasmapheresis should be reserved for more
resistant cases that have failed standard therapies or who are developing signi®cant side-effects from the
treatment. Plasmapheresis appears to be an effective modality for treating more aggressive forms of
pemphigus and should be considered as an important addition to current therapies.
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Mechanism of Action of IVIg in Pemphigus
J.-C. Bystryn
Department of Dermatology, Nyu Medical Center, New York, New York, U.S.A.
Background Pemphigus vulgaris (PV) is a blistering skin disease mediated by autoantibodies to
intercellular (IC) epidermal antigens. We evaluated the effectiveness of intravenous immunoglo-
bulin (IVIg) for the control of active disease, and the mechanism of action of this agent.
Methods Six patients with active PV unresponsive to conventional therapy were treated with
IVIg (400 mg/kg/day for 5 days) and concurrently given cyclophosphamide (100±150 mg/day).
The primary end-points were healing of skin lesions, and changes in the level of IC antibodies and
steroid dose. Two historical groups of patients treated conventionally with high doses of
corticosteroids and cytotoxic drugs (n = 11) or by plasmapheresis (n = 11) served as controls.
Results Within 2 weeks of initiating IVIg, the activity of PV was controlled in all but one case
and the extent of skin lesions was reduced on the average by 80%. Within 3 weeks, steroid doses
were reduced by an average of 41%. The improvement was more rapid than that in control patients
treated conventionally. Clinical improvement was associated with a rapid and selective decline in
IC antibodies whose levels decreased by 72% within 1 week of initiating IVIg. The rapidity and
extent of this decline were similar to that achieved by intensive plasmapheresis. The decline was
not due to blocking the synthesis or the immunological activity of IC antibodies by IVIg,
suggesting that it resulted from increased Ig catabolism.
Conclusions These results indicate that IVIg can effectively and rapidly control active PV and
suggests a novel explanation for its mechanism of action. It is that it increases the catabolism of
serum lgG, and that this results in a selective decrease in only pathogenic lgG antibodies as the level
of normal antibodies is maintained by those present in the IVIg preparation.
017
Novel Approaches to Therapy Based on Understanding Antigen Distribution
J. Stanley
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania,
U.S.A.
Understanding the pathophysiology of pemphigus leads to a rationale approach to therapy. For example, in
pemphigus foliaceus (PF) autoantibodies against desmoglein (dsg) 1 interfere with its adhesion function,
causing acantholysis. However, since in some areas there are two dsg isoforms (1 and 3) (e.g. in the deep
epidermis and throughout the mucous membranes), and in these areas the dsg 3 can compensate for
antibody-induced loss of function of dsg 1, preventing acantholysis. Similarly, induction of expression of
dsg 3 in the super®cial epidermis prevents PF-induced blisters.
The present therapy of pemphigus utilizes corticosteroids and various immunosuppressive drugs,
sometimes in combination with plasmapheresis. The rationale basis for immunosuppressive therapy and
plasmapheresis is that they lower the titer of pathologic autoantibodies (along with all other antibodies).
However, this cannot be the rationale for corticosteroids, because they act within days (when antibody
titers are not yet lowered) and even act locally. We hypothesize that corticosteroids might induce
transcription of dsg isoforms, providing protection from antidsg antibodies. Futhermore, innovative future
therapies might be directed towards inducing compensating dsg isoforms.
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Ancillary Care and Prevention of Complications in Pemphigus
V. Werth
University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
Prior to glucocorticoids (GCs), patients used to regularly die from pemphigus vulgaris. After GCs,
patients have tremendous morbidity and some mortality related to therapy, but don't die from the
disease itself. There are now more options for management of patients with PV, both in terms of
GC-sparing agents and in preventing some of the more devastating side-effects. Clearly, early
diagnosis and treatment of PV is important, and if patients don't respond or can't taper GCs, then
adjunctive therapies must be utilized quickly and routinely. Patient compliance is also crucial to a
good outcome of therapy.
Toxicities from GCs are related to higher doses and longer use, so early control of the disease is
really one of the more critical issues in preventing side-effects. Early attention to a number of
factors is important, including monitoring for weight gain, hypertension, hyperglycemia,
glaucoma, hyperlipidemias, infections, and electrolyte abnormalities. Abnormalities in the blood
pressure or labs should be carefully treated and followed.
Many advances have occurred relating to prevention of GC-induced bone loss. A baseline
DEXA scan of spine and hip bone density is now considered quite important, since pre-existing
osteopenia or osteoporosis necessitates prompt treatment, and monitoring of bone density can
detect patients losing bone at an unacceptable rate. Much of the bone loss from GCs occurs in the
®rst six months. There are many new therapies available to prevent loss of bone, and older patients
are often routinely put on these treatments to prevent further loss of bone.
Patients on GCs who develop pain or decreased range of motion of hips or other joints should
be promptly evaluated to rule out avascular necrosis. Early detection and treatment may prevent
progression to disabling arthritis and the need for joint replacement. The rate of GC taper is also
important. Although patients responding to GCs can be tapered fairly quickly at higher doses, it is
clear that below 20 mg/day, prednisone should be tapered more slowly, and below 10 mg/day,
patients often bene®t from reductions of as little as 1 mg/week. This allows for determining the
dose where lesions may recur, thus alleviating the need for rapid increases in GC dose with ¯ares.
Slow tapering at lower doses minimizes the development of the GC withdrawal syndrome, where
patients feel symptoms of fatigue, achiness, and malaise related to the GC taper.
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Cooperative Clinical Trials in PV: Where Are We?
V. Werth
University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
There is a complete absence of multicenter, randomized controlled trials to evaluate the therapies used in
PV. This has led to large variations in treatment of PV from university to university and practioner to
practioner. Reviews are based largely on case series and case reports, and there is little high quality evidence
to guide therapeutic decisions. Without studies, it is dif®cult at times to get insurance companies to pay for
potentially bene®cial therapies. The difference between conventional and alternative medicine in regards to
the treatment of PV is the desire to apply the scienti®c method and not to rely on anecdotes and theories in
directing therapeutic choices. We have yet to proceed beyond that desire for scienti®c clinical studies, and
it is clearly time for those truly interested in the treatment of PV to develop collaborative multicenter
protocols, similar to what has been done in cutaneous lymphoma, scleroderma, and many other orphan
diseases in internal medicine. There has been a lack of funding mechanisms for such an effort, and the
cooperation required between centers for multicenter, clinical trials, is quite distinct from the competitive
nature of basic science research.
In 1996, the Medical Dermatology Society (MDS) was formed, and one of the goals was to serve as a
coordinating body for the development of multicenter cooperative studies in medical dermatology, taking
advantage of the tools of modern electronic communication. After one two-hour session devoted to
therapy of PV, it became clear that there was no standardization of treatment, and that each center and even
each physician had evolved there own algorithm for management of patients with PV. Studies are dif®cult
because of the relative rarity of PV, the heterogeneous clinical presentation, and the heterogeneous
response to therapies.
It was determined, after extensive discussions with interested MDS members, collaboration with two
statisticians, and discussion with experienced trialists in the rheumatology community, that a study that had
a more uniform entry population would be the best initial study. To achieve this, it was decided to study
patients who were in the maintenance phase of their disease, but steroid-dependent. Such patients often
were unable to taper GCs below 15±40 mg prednisone a day without experiencing new skin lesions.
Preliminary data indicated that one potential GC-sparing agent in maintenance phase disease was dapsone,
and numerous anecdotes had been published over the years about the ef®cacy of dapsone in treating
patients with PV. Study outcomes related to reduction of GC doses, and the relatively uniform entry
population made a response relatively easy to assess. The study was initiated in 1997, with the support of
Jacobus Pharmaceuticals and ®ve centers have recruited 1/3rd of the needed recruitment, with just three
centers recruiting most of those patients. It is clear the study could be easily completed if more centers were
willing to participate. The issues have been bias, lack of time, and lack of a history/interest in doing these
types of studies. There is a belief that dapsone either doesn't work or de®nitely works, and both views were
shared during a poster presentation at the SID several years ago. Clearly, a study is the only way to sort out
these disparate observations.
Most successful active centers in the PV-dapsone study have a dermatologist who is double boarded in
medicine and dermatology, bringing the history of clinical trials that is so inculcated in the training of
internists, and run drug study units. There is a need to develop more individuals in dermatology who want
to participate in such studies, and the current trend of referring dif®cult management cases to academic
medical centers (AMCs), would make the AMC the likely place for these studies to occur.
There are clearlymanyother studies that need tobedone.Thegoal is to succeedat this focused, ``easy'' study,
develop a cooperative network of centers, and then expand to the many questions that exist related to
management of acute and chronic disease. What is the role of IVIG? Which immunosuppressive should we
really be using, after the ef®cacy, cost, and side-effects issues are considered? Who should receive
plasmapheresis? Doses maintenance with low-dose GCs after their disease is controlled alter the relapse rate?
There is a lot of work to do. The PV trial group meets annually at the AAD meeting, is happy to involve all
interested centers, and is truly looking for collaborative interactions. Funding mechanisms to link centers
should re¯ect the necessarily collaborative nature of such initiatives.
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Immunological Mechanisms of Self-Tolerance
E. Shevach
Laboratory of Immunology, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland,
U.S.A.
It is widely accepted that the development of autoimmune disease involves a breakdown in the
mechanisms that control self- vs. nonself discrimination. Thymic deletion of autoreactive T cells is
the primary mechanism that leads to tolerance to self-antigens. However, some autoreactive T cells
may escape thymic deletion or recognize antigens expressed only extrathymically. Studies over the
past 10 years have led to the identi®cation of a unique subset(s) of T cells whose primary role is to
suppress the activation of autoreactive T cells that have escaped passive mechanisms of tolerance
induction. One potent suppressor T cell population can be de®ned by the coexpression of CD4
and the Interleukin-2 receptor a-chain (CD25). CD4+ CD25+ T cells have been shown to be
involved in the suppression of several animal models of autoimmune disease including gastritis,
oophoritis, insulin-dependent diabetes, and in¯ammatory bowel disease. However, it has proven
dif®cult to determine their mechanism of action, antigen speci®city, or cellular targets. We have
recently developed in vitro model systems that mimic the function of these cells in vivo.
CD4+ CD25+ T cells are nonresponsive to stimulation by antigen or mitogens; when coculutred
with CD4+ CD25- T cells, the CD4+ CD25+ T cells suppress proliferation and effector cytokine
production by a cytokine-independent, cell contact-dependent mechanism. CD4+ CD25+ T cells
with identical properties have also been described in human peripheral blood. Augmentation of the
function of these CD4+ CD25+ suppressor T cells may represent a therapeutic option for the
treatment of autoimmune diseases.
021
Peptide Based Vaccine Strategies
M. Rico and J. Rasrmussen*
New York University School of Medicine, New York, New York, U.S.A.; Fujisawa Healthcare, Inc, Illinois,
U.S.A.; *Genzyme, Inc., Cambridge, Massachusetts, U.S.A.
Vaccination has been used for over 100 years to speci®cally induce or ameliorate immune responses n
humans. Vaccination advantages over conventional disease treatment include that the targeting is selective,
speci®c, and durable. In the case of pemphigus, development of a vaccine to down-regulate or eliminate
pathogenic desmoglein responsive immune elements in patients, or prevent development of desmoglein
speci®c responses in susceptible individuals would obviate the need for glucocorticoids and
immunosuppressive regimens. The feasibility of a vaccine approach stems from advances in our
understanding of the genetics of this disease, identi®cation and sequencing of the major targets, and
advances in our understanding of vaccine irnmunobiology,
Current strategies for vaccine development relevant to autoimmune diseases focus on the generation of
regulatory T cells or immune deviation via: (1) immunization with peptides or altered peptide ligands; (2)
use of MHC-peptide complexes with or without a cytotoxic fusion partner; and (3) induction of high-zone
a tolerance using native peptide ligands. All 3 of these strategies are currently in development for other
autoimmune processes including allergic rhinitis, rheumatoid arthritis, and multiple sclerosis.
The goal of vaccine immunotherapy is to anergize or delete disease-speci®c CD4+ T cells, The
speci®city of this response is obtained by employing peptides presented by the disease-associated MHC
Class II molecules, in the case of pemphigus vulgaris, DR(3 1*0402. Identi®cation of the relevant antigenic
domains, or epitopes. that are important in the generation of an immune response, is critical in the
development of a vaccine. Preliminary investigations by several investigators have identi®ed B and T cell
epitopes in the extracellular domain of desmoglein 3. We have continued and extended this work to more
precisely map T cell epitopes in this region. Our preliminary results support previous studies by
Wucherpfenning et al that identi®ed T cell epitopes in desmoglein 3 that bind to MHC Class II molecules
and are recognized by peripheral blood lymphocytes from patients with pernphigus vulgaris.
022
Immunoablative Therapy of Refractory Pemphigus
R. Brodsky, H. Nousari, R. Jones, and G. Anhalt
Johns Hopkins Hospital, Baltimore, Maryland, U.S.A.
Pemphigus encompasses a group of autoimmune mucocutaneous blistering diseases characterized
by two features: a) disruption of the cell-cell adhesion of strati®ed squamous epithelia and (b) the
presence of pathogenic IgG autoantibodies reacting against desmosomal adhesion molecules. The
three major subsets of the disease are pemphigus vulgaris (PV), pemphigus foliaceus (PF), and
paraneoplastic pemphigus (PNP). We have previously demonstrated that high-dose cyclopho-
sphamide (CY) without bone marrow transplantation (BMT) can induce durable treatment-free
remissions in a variety of severe autoimmune disorders including aplastic anemia, systemic lupus
erythematosus, and autoimmune hemolytic anemias. We now report the results of high-dose Cy
(50 mg/kg/day for 4 consecutive days) in 6 patients with refractory PV. Eligible patients had
persistent disease activity despite treatment with mycophenolate mofetil (MMF) and/or
azathoprine (aza) and were dependent on corticosteroids. Patients had a median age of 33.5
(range, 27±47) years, a median disease duration of 3.5 (range, 2±5) years, and a median prednisone
dosage of 50 (range, 30±60) mg/day. All patients were refractory to aza; 5 were refractory to MMF.
High-dose Cy was well tolerated; common toxicities included reversible alopecia, transient
nausea/vomiting, febrile neutropenia (2 patients). The median time to a neutrophil count of
0.5 3 109/L was 11.5 (range, 11±18) days; the median number of packed red cell transfusions was 2
(range, 0±4) units and the median number of platelet transfusions was 1 (range, 0±2). Complete
remission (CR) was de®ned as: resolution of all skin lesions and reduction of circulating pemphigus
antibody levels to < 1 : 20. Partial remission (PR) was de®ned as: improvement in skin lesion and
reduction of pemphigus antibody levels to < 1 : 80. Four patients have achieved a CR and 2
patients are in a PR with a median follow-up of 6 (range, 1±30) months. The median prednisone
dosage after therapy in 2.5 (range 2.5±10) mg/day. Additional follow-up and a larger number of
patients are needed; however, these preliminary data suggest that high-dose Cy can produce
durable complete remissions in patients with refractory PV.
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Gene Therapy to Treat Autoimmune Diseases
C. Fathman
Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of
Medicine, Stanford, California, U.S.A.
CD4+ T cells have been implicated in the pathogenesis of several autoimmune diseases such as rheumatoid
arthritis (RA), multiple (MS) and TID (IDDM). Autoantigen-speci®c T cells have tissue-speci®c homing
properties, suggesting that these cells may be ideal vehicles for the local delivery of ``immunoregulatory''
products. We tested this hypothesis in animal models of autoimmune disease by using autoantigen-speci®c
CD4+ T hybridomas, following gene transfer, as vehicles to deliver ``immune-regulatory proteins'' for the
treatment animal models of human autoimmune diseases. Autoantigen-speci®c T.cells were transduced to
express the interleukin (IL)- 12 antagonist, IL-12p4O, using retroviral vectors encoding IL-12p40 cDNA.
Transfer of relevant autoantigen-speci®c IL-12p40 producing CD4+ T cells after immunization
signi®cantly inhibited the development of either CIA or EAE, while cells transduced with the vector
control had no effect. Additionally, islet speci®c T cells, transduced to express IL-12 p40 blocked the
adoptive transfer of IDDM into immunocompromised NOD mice. The development of CIA or EAE was
inhibited as a result of local suppression of in¯ammatory autoimmune responses by the transduced
autoantigen speci®c T cells. Detection of bioluminescent autoantigen-reactive T cell hybridomas following
transfer into immunized mice demonstrated accumulation and retention in in¯amed tissues. The bene®cial
effect of IL-12p40-transduced T cells required TCR speci®city against the relevant autoantigen since
MBP-speci®c IL-12p40-expressing T cells, that produced equivalent amounts of IL-12p40 as CII-speci®c
IL-12p40-expressing T cells, were therapeutic in an EAE model, but had no effect in ameliorating CIA and
vice versa. Thus, although MBP-speci®c T cells, that could ameliorate EAE were found to migrate into the
in¯amed joints of CIA mice, they were not retained there, and no therapeutic bene®t on CIA was
observed. These results indicated that the local delivery of IL-12p40 by autoantigen-speci®c T cells
inhibited in¯ammatory autoimmune disease by suppressing the response at the site of in¯ammation. More
recent studies have suggested that bone marrow derived dendritic cells, transduced to express
immunoregulatory proteins, were also effective in ameliorating certain autoimmune diseases. Traf®cking
studies of these cells, using bioluminescence, revealed unexpected homing to in¯amed tissues. We
conclude that modifying antigen-speci®c T cells or bone marrow derived dendritic cells by retroviral
transduction for expression of immunoregulatory proteins is a promising therapeutic strategy for the
treatment of human in¯ammatory autoimmune diseases.
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Pemphigus Vulgaris (PV): The Cleveland Clinic Experience 1987±2000
C. Camisa and W. Kurz
Cleveland Clinic Foundation (CCF), Department of Dermatology Cleveland, Ohio, U.S.A.
The purpose of the study was to assess the clinical and histological pro®le and treatment outcomes
in a consecutive group of patients with PV followed at one center. A retrospective chart analysis
with telephone follow-up on 56 PV patients seen at the CCF between 1987 and 2000 was
performed. The gender of patients was 68% female and the mean age of onset of PV was 48 years.
The areas of involvement: 56 (100%) oral, 38 (67.9%) skin, 16 (28.6%) genital, 15 (26.8%)
nasal, < 25% pharyngeal, ocular, laryngeal, anal, or esophageal involvement (in descending order).
63 (96.9%) of 65 biopsies in 53 patients were consistent with PV. 43 (81.1%) of 53 direct
immuno¯uorescence tests performed in 46 patients were consistent with PV. 45 (90.0%) of the 50
indirect immuno¯uorescence tests performed were positive for PV. 44 (78.6%) achieved complete
remission (CR) with a median duration of 17 months. The medications used at onset of CR were
prednisone in 30 (68.2%), dapsone in 10 (22.7%), azathioprine in 8 (18.2%), and no treatment in 5
(11.4%), topical corticosteroids, cyclophosphamide, oral methyl prednisolone, tetracycline,
niacinamide, and mycophenolate (in descending order). The median time needed to achieve
CR after the ®rst visit was 9 months. The majority of PV patients were females. Middle age was the
time at which the disease most often presented. The oral cavity was involved in all cases over the
course of the disease. Histologic examination of biopsy material con®rmed the diagnosis of PV
most reliably. CR was achieved in the majority of patients using combinations of medications.
Drugs associated with CR most frequently were prednisone, dapsone and azathioprine either alone
or in combination.
P002
Levels of IgG, IgG1 and IgG4 Antibodies to Desmoglein 3 in Sera of Three Patients with
Pemphigus Vulgaris Undergoing Pulse Intravenous Methylprednisolone Therapy
M. Dmochowski and M. Bowszyc-Dmochowska
Department of Dermatology, University School of Medicine, Poznan, Poland
It is known that patients with pemphigus vulgaris (PV) respond to oral immunosuppressive agents
before titers of their pemphigus antibodies start to decrease. Moreover, IgG1 and IgG4 pemphigus
antibodies predominate in sera of patients with this disease.
The aim of this study was to evaluate the levels of serum IgG, IgG1 and IgG4 antibodies to
desmoglein 3 in patients with PV undergoing pulse intravenous methylprednisolone therapy.
Three patients were administered 3 g of methylprednisolone IV over 3±6 days. Their sera were
checked for the levels of IgG, IgGI and IgG4 antibodies a day before starting a pulse and a day after
completing the pulse with indirect immuno¯uorescence on normal human skin, and desmoglein 3
Elisa (MBL) modi®ed to evaluate not only IgG but also IgGI and IgG4 antibodies. Despite the
rapid cessation of a formation of new blisters and healing of already established lesions, there was no
decrease of levels of serum IgG, IgG1 and IgG4 antidesmoglein 3 antibodies.
Therefore, it seems that antidesmoglein 3 antibodies alone might not be suf®cient to maintain a
disease process in PV.
P003
Immunological Follow-Up of Patients with Pemphigus Vulgaris
M. Hertl, A. Stauber, R. Eming, R. Spaeth, and R. Riechers
Department of Dermatology, University of Erlangen, Germany
There is major interest in de®ning immunological markers that can be applied to monitor the
activity of pemphigus vulgaris (PV). We thus sought to correlate the clinical activity of PV with T
helper (Th) cell and auto-antibody (Ab) reactivity against desmoglein 3 (Dsg3), the major
autoantigen of PV.
Reactivity of Ab subtypes against Dsg3 was analysed by immunoblot and ELISA analysis
utilizing baculovirus-derived recombinant Dsg3. The cell reactivity against Dsg3 was quantitated
by ELISPOT analysis.
A total of 41 patients with PV were examined by immunoblot analysis. In active PV, Dsg3-
reactive IgG1 was detected in 20/33 (60.6%), IgG4 in 29/33 (87.9%), IgA in 21/33 (63.6%) and
1gE in 4/33 (12.1%) sera. Sera from patients with remittent PV contained Dsg3-reactive IgGl in 6/
8 (75%) and IgG4 in 5/8 (63%) but not Dsg3-reactive IgA and 1gE. By ELISA, sera from patients
with active disease contained titers of Dsg3-reactive IgG4 that exceeded those of IgG1 and IgA by
a factor of at least 2. By ELISPOT assay, three patients with active oral PV had 3.8 6 1.4 Dsg3-
reactive Th1 cells and 9.1 6 2.1 Th2 cells/105 PBL while 0/3 PV patients in remission had
detectable autoreactive Th cells/105 PBL. Our study suggests that, in addition to quantitating total
IgG reactivity to Dsg3, the titers of Ab subtypes may be helpful therapeutic and/or prognostic
markers in PV. Quantitation of autoreactive Thi and Th2 cells may represent an additional highly
sensitive parameter of disease activity: and may provide further insight into the role that
autoreactive TH cells play in the pathogenesis of PV.
P004
Pemphigus Erythematosus: An Attempt to Rede®ne the Clinical and
Immunopathological Features
F. Karlhofer, K. Slupetzky, M. Amagai, B. Volc-Platzer, R. Kimbauer, and G. Stingl
University of Vienna Medical School, Vienna Austria and Keio University School of Medicine, Tokyo, Japan
Diagnostic criteria for Pemphigus erythematosus (PE, Senear±Usher syndrome) are controversial.
PE was originally described as a variant of pemphigus with additional features of lupus
erythematosus. Other associated diseases included thymoma, myasthenia gravis and rheumatoid
arthritis. By direct immuno¯uorescence (DIF) PE typically shows intercellular substance (ICS) and
basement membrane zone (BMZ) staining. Its diagnosis is often based on the localization of
eruptions in seborrheic and/or malar areas and currently PE is frequently regarded a localized early
form of pemphigus foliaceus (PF).
In this report we describe two patients with erythematous erosive skin lesions without mucosal
involvement. The ®rst patient with 11 years' medical history of seropositive rheumatoid arthritis
showed generalized erosive lesions with crusts whereas the second patient with an unremarkable
medical history displayed a single erosive lesion with crusts con®ned to the forehead. Lesional
biopsies showed super®cial acantholysis; DIF testing revealed an ICS staining pattern with IgG and
C3 in both patients. In addition, a prominent granular deposition of C3 along the BMZ was
present. Indirect immuno¯uorescence (IIF) performed on monkey esophagus found circulating
anti-ICS antibodies with a titer of 320 and 80, respectively; using normal human ``salt split skin'' as
a substrate both patients' sera contained circulating anti-BMZ IgG antibodies that bound to the
epidermal side. By ELISA and by Westernblot desmoglein-1 (Dsg-1) speci®c antibodies were
detected in the ®rst patient's serum. In contrast, desmoglein-3 (Dsg-3) speci®c antibodies were
present in the serum of the second patient. In addition, both sera contained antibodies targeting a
230-kDa band comigrating with the bullous pemphigoid antigen-1 (BPAg-1). Laboratory studies
revealed a positive rheumatoid factor and elevated antinuclear antibodies in the former but not in
the latter patient. Despite the differences in the extent of skin involvement, in autoantibody
reactivity against desmogleins and in associated diseases, we believe that both patients qualify as PE
because they show similar super®cial primary lesions without involvement of mucous membranes
and both display a combined ICS and BMZ staining pattern by DIF.
Thus, PE can occur as a generalized as well as a localized disease and does not represent simply a
localized form of PF. In addition, we propose that PE is not necessarily associated with other
autoimmune diseases and the PE sera not only target Dsg-1 but can also target Dsg-3. The
signi®cance of the antiBPAg-1 antibodies in both patients' sera escapes us at the present time; while
they may simply represent an innocent bystander phenomenon it is tempting to speculate that they
serve as a trigger of the antidesmoglein mediated disease. Larger studies are warranted to investigate
if the presence of anti-BPAg-1 antibodies is of regular occurrence in PE.
P005
IgA Pemphigus. Report of Five Cases with Different Therapy Approach
B. Marinovic and J. Lipozencic
Department of Dermatology and Venerology, Zagreb University Hospital Center, Zagreb, Croatia
IgA pemphigus is relatively newly described, rare, autoimmune-mediated blistering disease
characterized by intraepidermal neutrophilic pustules, intercellular IgA deposits, and circulating
IgA antibodies in some cases.
In two year period ®ve female patients with IgA pemphigus presented to our Department.
Patients were aged between 30 and 77 years and presented with different clinical pictures ± two of
them presented with pruritic erythematous patches of their forehead, scalp and intertriginous areas
which were partly covered with yellowish crusts, other two patients had vesicles, erosions and
crusts in periumbilical and presternal region. One patient had vesiculopustules on her trunk and in
the scalp. In histopathology there was ®nding of intraepidermal blister in the upper epidermis with
acantholitic cells in two of them and without acantholitic cells in others. Lymphocytic spongiosis
was also present. In direct immuno¯uorescence in all patients IgA intercellularly was detected, in
two of them there was also ®nding of C3 in the basement membrane zone, and in one patient IgA
was detected intercellularly and in the basement membrane zone. In three patients, indirect
immuno¯uorescence was positive for IgA intercellularly. In four patients therapy with
prednisolone in a dose of 1 mg/kg body weight was introduced. In two of them remision was
achieved with this therapy, in one patient azathioprine was introduced as adjuvant therapy, along
with corticosteroid dose reduction (because of steroid diabetes in a patient), and in other one we
had to introduce Dapsone in a dose of 150 mg daily, because of poore response to prednisolone. In
®fth patient we introduced Dapsone as a drug of choise, which resulted in considerable
improvement in 10 days.
We conclude that IgA pemphigus is relatively benign type of pemphigus disease with speci®c
histopathological and immuno¯uorescent ®ndings, with different clinical presentations as well as
with different possibilities of therapy approach.
P006
Pemphigus Foliaceus as a Model of Polygenic Disease
P. Martel, D. Gilbert, M. Busson, L. Drouot, P. Joly, D. Charron, and F. Tron
INSERM U519, Rouen, France, Hospital Saint Louis, Paris, France
We previously described a silent single nucleotide polymorphism (SNP) of the desmoglein 1 gene
which consists of a T to C transition at position 809. To investigate the role of genetic background
in pemphigus foliaceus and to ask whether PF, like other autoimmune diseases, is expressed as a
complex trait, we simultaneously examined the role of major histocompatibility complex (MHC)
class II polymorphism and SNP(809) in PF susceptibility.
Thirty-one Caucasian French patients and 84 healthy Caucasian French controls were studied by
PCR-RFLP for SNP(809) genotyping and by PCR-SSO and PCR-SSP for DRB1 and DQB1
typing.
This analysis con®rmed involvement of DRB1*04 (p = 0.01) and DRB1*14 (p = 0.04) generics
in disease susceptibility and individualized DRB1*0102 (p = 0.04), DRB1*0402 (p = 0.02),
DRB1*0406 (0.003), and DRB 1*1404 (p = 8.10±4) as susceptibility MHC class II alleles in French
PF patients. Homozygous C/C(809) genotype was also found associated with the disease
(p = 0.03). Furthermore, patients with both DRB1*04 and C/C(809) had a very signi®cant risk to
develope PF (p = 1.10±4) and comparison, by logistic regression, of susceptibility given by both risk
factors showed a signi®cant interaction between DRB1*04 and C/C(809).
DRBl *04 and C/C(809) are signi®cant risk factors to PF and interact to enhance disease
susceptibility. PE therefore constitutes another demonstrative example of the role of epistatic
interaction of individual genes in autoimmune diseases susceptibility.
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The Pathogenic Study of ECI-2 of Pemphigus Vulgaris Antigen
M. Pan, J. Zhen, X. D. Kang, W. P. Li, and F. Xue
Ruijin Hospital af®liated to Shanghai Second Medical University, Dermatology, Shanghai, China
Purpose Pemphigus Vulgaris autoantigen (PVA) is a transmembrane glycoprotein, which is called
desmoglein 3 (Dsg3). It has ®ve extracellular domains (ECI to EC5). The purpose is to test
whether EC1-2 is immunogenic domain and whether its antibody is pathogenic by establishing
neonatal mouse model of PV.
Methods A segment of the human Dsg3 cDNA (about 1100 bp in the amino terminus,
including EG1-2) was subcloned into glutathione S-transferase (GST) gene by pGEX-4T-l
expression vector, and the recombinant vector was used to generate GST fusion protein (FP)
containing the ECI-2 segment of Dsg3. The FP was expressed in E.coli. JMIO9 and was puri®ed by
glutathione af®nity chromatography. It was con®rmed by nucleotide sequence analysis and
immunoblotting with anti-GST antibody. We also tested PV patients by immunoblotting analysis
with puri®ed EC1-2 FP. New Zealand white rabbits were immunized with the EC1-2 FP. IgG
fraction was got from the antisera of rabbit by precipitation with caprilic acid, followed by DEAE-
52 ion-exchange chromatography. Then it dialyzed agaist phosphate-buffered saline (PBS, pH7.4)
and concentrated with Polyethylene glycol 20000 to 40mg/mI. Puri®ed lgG fraction was injected
subcutaneosly into the upper back skin of neonatal BALB\c mice (<24h of age). The lgG dose was
200pl each time, two doses 5h apart, about lOmg/g body weight. Neonatal mice were examined
16h after injection. Skin was studied by light microscopy, electronic microscopy and direct
immuno¯uorescence (DIF). Serum was assayed by indirect immuno¯uorescence (IIF).
Results Immunoblotting analysis of EC1-2 FP with 22 PV patients' sera demonstrated that 17
PV patients were positive. By DIF, the skin of mice showed lgG antiserum deposition on the cell
surface of acantholytic cells. By IIF, using normal neonatal mouse skin as substrate, the titer of lgG
was 40-80. Histologically, we can see stratum corneum detached and acantholysis, but no blisters in
the epidermis by light microscopy. Electronic microscopy examination con®rmed that wider
intercellular spaces (105) occurred in the regions of the cell surface.
Conclusions These results show that EC1-2 in the amino terminus of Dsg3 is immunogenic in
PV and its antisera is pathogenic. The anitbody of EC1-2 FP can induce a neonatal mouse model
of PV which gives a tool of studying autoimmune disease.
P008
Direct Immuno¯uorescence of Skin, Oral Mucosae and Esophagus in Pemphigus
Vulgaris Patients in Remission
M. Pulido-Galvan, F. Barzallo-Viteri, and G. Leon-Dorantes
Hospital General de Mexico, Mexico City, Mexico
Objective To compare the results of skin, oral mucosae and esophagus direct immuno¯uorescence
(DIF) tests of patients with pemphigus vulgaris in the remission stage of treatment.
Design Cross-sectional study. Setting: Tertiary care center.
Methods Female or male adult patients with history of con®rmed pemphigus vulgaris in
remission stage (absence of skin or mucosal lesions for more than 6 months, with <20 mgs.
prednisone /day) , with informed consent had three biopsies: skin, oral mucosae, and esophageal
mucosae. Esophagus biopsies were obtained by endoscopic means. Tissues were tested with a
standard method of direct immuno¯ourescence.
Results 8 female and 2 male patients, 46 (S.D.: 12.2) years of mean age and 11 (S.D: 6.2) months
mean time under remission were included. 4 patients were not taking already prednisone. Nine
had objective esophageal abnormalities when endoscopy was performed. DIF was positive in 7
esophagus biopsies, 4 oral mucosae biopsies and only 3 skin biopsies. Sensitivities of DlFskin test
and of DIF oral mucosae test were 43% and 57% as compared to DIF esophagus mucosae test.
Conclusions A negative DIF esophageal mucosae test may be useful when the decision to stop
treatment becomes an issue.
P009
Kininogens-Kallikreins-Kinin System in Plasma of Brazilian Patients with Pemphigus
Foliaceus
T. Rosatelli, R. Jovilliano, M. Reis, A. Roselino, and E. Donadi
School of Medicine of Ribeirao Preto-USP, 2- School of Pharmaceutical Sciences of Ribeirao Preto-USP,
Brazil
Objective Pemphigus foliaceus (PF) is an autoimmune bullous disease affecting the skin caused by
IgG4 autoantibodies against desmoglein. Considering that are few studies involved kallilcrein-kinin
patterns in PF, we evaluated activation of kinins in this condition.
Methods Fifteen patients (11 men and 4 women) presenting active PF with nikolsky sign
positive, 15 controls subjects were studied. The concentration of total kininogen (TKg), low
molecular weight kininogen(LKg) and was determined by ELISA(J Reumathol., 25 : 1±
4,1988).The activity of plasma kallikrein and tissue kallikrein were evaluated upon selective
substrates.
Results The results are shown in the table and indicate the median values of kininogens and
kallikreins parameters, we observed decreased kininogens in plasma of PF and impaired values of
tissue kallikrein and plasma kallikrein of PF patients compared with controls.
Conclusion The impaired levels of kallikrein and a decreased kininogens suggested a possible
activation of kinin system and participation of acantholysis observed in PF.
P010
Dendritic Cells in Endemic Pemphigus Foliaceus (EPF)
M.P. Chiossi, R.S. Costa, and A.M. Roselino
University of Sao Paulo, Faculty of Medicine of Ribeirao Preto, Brazil
To elucidate the pathophysiology of EPF, dendritic cells (DC) were measured in skin biopsies
(lesional skin) from 22 EPF patients and in normal thoracic sun-protected skin of a non perilesional
area in 13 of them. Controls consisted of normal thoracic skin from 8 cadavers and from 12 women
submitted to breast plastic surgery. DC were identi®ed with anti-CDIa and quanti®ed by
morphometry. Epidermal DC numbers in lesion [60.18 DC/mm2, 5.00 DC/mm basement
membrane (BM), 3.55 DC/mm stratum corneum (SC)] and normal skin (28.45 DC/mm2, 2.50
DC/mmBM, 2.87 DC/mmSC) of EPF patients were similar to those for the plastic surgery (72 35
DC/mm2, 4.53 DC/mmBM, 4.42 DC/mmSC) and cadaver controls (47.15 CD/mm2, 2.53 CD/
mmBM, 2.42 CD/mmSC). Dermal DC number in lesions (0.98 DC/mmBM) of EPF patients was
similar to the plastic surgery control (0.48 DC/mmBM), but higher than in the cadaver controls
(0.13 DC/mmBM, p < 0.05). The epidermal DC/mmMB/dermal DC/mmMB ratio was lower in
lesional EPF skin (5.72) than in controls (9.22, p < 0.05), con®rming the higher DC number in
dermis in the former. In the same patient, the amounts of epidermal and dermal DC were higher in
EPF lesional skin (61.50 DC/mm2, 5.49 DC/mmBM, 6.64 DC/mmSC, 0.86 dermal DC/
mmBM) than in normal skin (28.45 DC/mm2, 2.50 DC/mmBM, 2.87 DC/mmSC, 0.04 dermal
DC/mmBM). A direct association was found between dermal DC/mmMB in lesional skin of EPF
patients and titration of serum antibodies by IFI (r = 0.4729, p < 0.O5), con®rming that dermal DC
could play an important role in EPF pathogenesis. We may propose that DC may be in transit
through the dermis towards the regional lymph nodes, stimulating T lymphocytes to produce
autoantibodies.
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Detection of Pemphigus Autoantibodies by Immunoblot in Tunisian Patients
M. Kallel-Sellami, M. Zitouni,* M. Ben Ayed,² M. Mokni,³ D. Gilbert,§ F. Tron,§ A. Zahaf,¶
M. Kamoun,** A. Ben Osman-Dhahri,³ H. Masmoudi,² and S. Makni*
*Immunology Department, ³Dermatology Department, La Rabta Hospital, Tunis, Tunisia; ²Immunology
Department, ¶Dermatology Department, CHU Sfax, Tunisia; §INSERM U519 Rouen, France;
**Dermatology Department, Charles Nicolle Hospital, Tunis, Tunisia
Introduction Pemphigus is a rare organ-speci®c autoimmune blistering disease involving skin and
mucous membrane. Autoantibodies are pathogenic and are directed against desmosomes adhesion
molecules . Pemphigus foliaceus (PF) antigen is desmoglein 1 (Dsg 1) and Pemphigus vulgaris (PV)
antigen is desmoglein 3 (Dsg3). We looked in this study for the different autoantigens recognized
by autoantibodies with immunoblot method in Tunisian pemphigus patients.
Patients and methods
Patients 43 with PF, 10 male (mean age 52 years) and 33 female (mean age 35 years), 35 with
PV, 6 male (mean age 50 years) and 29 female (mean age 46 years).
Methods Immunoblot using human epidermal extracts for detecting IgG class and subclasses of
different autoantibodies.
Results Anti-Dsg 1 and anti-Dsg 3 were found in PF patients in 65% (28/43) and 2% (1/43), but
in PV patients they were found in 11,4% (4/35) and 45,7% (16/35)
Conclusion Most of the PF patients are young women. This data was previously reported in
Tunisian epidemiological studies. Anti-Dsg 1 characterize Tunisian PF patients and anti Dsg 3
characterize Tunisian PV Patients. Updated January 15, 2000.
740 ABSTRACTS THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
